TOKYO -- With antibody treatments seen as the best weapon against COVID-19, Japan and the country's top drugmaker have turned to a type derived from the plasma of recovered patients, rather than the lab-made varieties used on U.S. President Donald Trump.
An alliance of companies and health organizations, including Takeda Pharmaceutical is working on an immunoglobulin-based coronavirus treatment, and a Phase 3 clinical trial began in October across multiple countries. Results may become available before the end of the year.
